Review
Immunology
Elodie Renaude, Marie Kroemer, Christophe Borg, Paul Peixoto, Eric Hervouet, Romain Loyon, Olivier Adotevi
Summary: The review discusses the role of CD4(+) Th cells in anticancer immunity and emphasizes the importance of epigenetics. Research describes how epigenetic factors regulate the differentiation and recruitment of CD4(+) T cells. Furthermore, the potential of using epigenetic drugs to enhance anticancer immunotherapy is explored.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
MacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake Ceccarelli, T. J. Langer, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, Daniel Abate-Daga, James J. Mule, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Summary: This study highlights the importance of neoantigen-specific CD4(+)T cells within tumor-infiltrating lymphocytes (TILs) as a potent source of tumor-specific effectors. The findings suggest that these CD4(+)T cells play a significant role in antitumor immunity and should be included in future adoptive cell therapy (ACT) protocols to improve treatment efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Multidisciplinary Sciences
Frank J. Lowery, Sri Krishna, Rami Yossef, Neilesh B. Parikh, Praveen D. Chatani, Nikolaos Zacharakis, Maria R. Parkhurst, Noam Levin, Sivasish Sindiri, Abraham Sachs, Kyle J. Hitscherich, Zhiya Yu, Nolan R. Vale, Yong-Chen Lu, Zhili Zheng, Li Jia, Jared J. Gartner, Victoria K. Hill, Amy R. Copeland, Shirley K. Nah, Robert Masi, Billel Gasmi, Scott Kivitz, Biman C. Paria, Maria Florentin, Sanghyun P. Kim, Ken-ichi Hanada, Yong F. Li, Lien T. Ngo, Satyajit Ray, Mackenzie L. Shindorf, Shoshana T. Levi, Ryan Shepherd, Chris Toy, Anup Y. Parikh, Todd D. Prickett, Michael C. Kelly, Rachel Beyer, Stephanie L. Goff, James C. Yang, Paul F. Robbins, Steven A. Rosenberg
Summary: Mapping TCRs from metastatic tumors to single-cell transcriptomes identified tumor-specific expanded neoantigen-specific TILs with dysfunctional phenotypes. Prospectively testing signature-derived clonotypes demonstrated TCR recognition of tumor antigens, suggesting a common metastatic TIL exhaustion program. NeoTCR signatures enable successful TCR prediction for cancer immunotherapy based on TIL transcriptomic states.
Review
Genetics & Heredity
Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Nikolaos Papadopoulos, Konstantinos Papanikolopoulos, Georgios Aloizos, Christos Damaskos, Nikolaos Garmpis, Anna Garmpi, Dimitris Matthaios, Michalis. V. V. Karamouzis
Summary: Autophagy is a crucial process for cell degradation and recycling, which affects cellular functions and is associated with tumorigenesis, tumor-stroma interactions, and resistance to cancer therapy. It influences the tumor microenvironment and plays a key role in immune cell functions, neo-antigen presentation, and cross-presentation. Autophagy is currently an important target in immunotherapy.
Article
Genetics & Heredity
Jingcheng Wu, Wenfan Chen, Yuxuan Zhou, Ying Chi, Xiansheng Hua, Jian Wu, Xun Gu, Shuqing Chen, Zhan Zhou
Summary: In this study, the authors present an updated version, TSNAdb v2.0, of the tumor-specific neoantigen database (TSNAdb). This version offers new features, including stricter criteria for neoantigen identification, predicted neoantigens derived from three types of somatic mutations, and the collection of experimentally validated neoantigens categorized according to experimental level.
GENOMICS PROTEOMICS & BIOINFORMATICS
(2023)
Review
Immunology
Zhiheng Wu, Yu Zheng, Jin Sheng, Yicheng Han, Yanyan Yang, Hongming Pan, Junlin Yao
Summary: This article comprehensively reviews the origin, distribution, and functions of DN T cells, focusing on their roles in inflammation, immune disorders, and cancer. It also discusses the recent advances in DN T cell-based therapy for cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Karen Kai-Lin Fang, Jongbok Lee, Ismat Khatri, Yoosu Na, Li Zhang
Summary: The use of allogeneic CAR4-DNTs as adoptive cell therapy for T-cell malignancies is effective. CAR4-DNTs can effectively target T-ALL and PTCL and have superior cytotoxicity compared to empty-vector transduced DNTs.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Immunology
Zheying Zhang, Manman Lu, Yu Qin, Wuji Gao, Li Tao, Wei Su, Jiateng Zhong
Summary: Cancer immunotherapy enhances the body's immune response to target and eliminate cancer cells, with a focus on the emerging approach of tumor neoantigens. Studies have shown the relationship between neoantigens and T cell recognition of cancer cells, highlighting the potential of vaccines developed against these specific antigens in clinical trials.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Joseph S. Dolina, Joey Lee, Spencer E. Brightman, Sara McArdle, Samantha M. Hall, Rukman R. Thota, Karla S. Zavala, Manasa Lanka, Ashmitaa Logandha Ramamoorthy Premlal, Jason A. Greenbaum, Ezra E. W. Cohen, Bjoern Peters, Stephen P. Schoenberger
Summary: This study explores how the response to immune checkpoint blockade can be improved for aggressive low-TMB squamous cell tumors by combining intermolecular epitope spreading and immune checkpoint blockade, leading to the eradication of established large tumors.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Oncology
Natalia Plewa, Lucia Poncette, Thomas Blankenstein
Summary: This study suggests that HLA-DR4-restricted TCRs specific for the TGF beta R2(-1) recurrent neoantigen could be valuable candidates for adoptive T cell therapy in cancer patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Guidong Zhu, Qing Zhang, Junwen Zhang, Fusheng Liu
Summary: CAR-T therapy shows promising results in treating blood cancers, particularly leukemia, but its effectiveness for solid tumors like glioblastoma is limited. The immunosuppressive microenvironment of malignant gliomas hinders CAR-T therapy and restricts its efficacy, despite ongoing research efforts to enhance its potential clinical applications.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Jennifer R. Richardson, Anna Schoellhorn, Cecile Gouttefangeas, Juliane Schuhmacher
Summary: CD4+ T cells, bearing the CD4 co-receptor, are a heterogeneous group of T lymphocytes that play a crucial role in the antitumor immune response by directly or indirectly killing tumor cells. Research is increasingly focusing on both CD4+ and CD8+ T cell subsets in cancer immunotherapy approaches.
Article
Oncology
Selma Bekri, Reunet Rodney-Sandy, Diana Gruenstein, Anna Mei, Bjarne Bogen, John Castle, Daniel Levey, Hearn Jay Cho
Summary: This study demonstrates that a vaccine targeting a tumor-specific neoantigen efficiently induces CD4 T cell-mediated tumor protection in a mouse model. The vaccine does not directly induce cytotoxic activity in CD4 T cells, but activation of CD8 CTL against tumor-associated antigens not present in the vaccine is a major mechanism of tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Biochemistry & Molecular Biology
Seongmin Jeong, Nawon Jang, Minchae Kim, Il-Kyu Choi
Summary: While CD8+ cytotoxic T cells have traditionally been considered the main drivers of tumor control, the role of CD4+ helper T cells in anti-tumor immunity has been underestimated. Recent studies on intra-tumoral T cells using genomic technologies have led to a reassessment of CD4+ T cells' indirect helper role. Accumulating evidence suggests that CD4+ T cells can directly kill tumor cells in a MHC-II-dependent manner, highlighting their potentially critical contribution to immune responses against a wide range of tumor types.
Article
Biochemistry & Molecular Biology
Can Cui, Jiawei Wang, Eric Fagerberg, Ping-Min Chen, Kelli A. Connolly, Martina Damo, Julie F. Cheung, Tianyang Mao, Adnan S. Askari, Shuting Chen, Brittany Fitzgerald, Gena G. Foster, Stephanie C. Eisenbarth, Hongyu Zhao, Joseph Craft, Nikhil S. Joshi
Summary: The study found that the enrichment of TFH cell transcriptional signature in lung adenocarcinoma patients is correlated with GC B cell signature and prolonged survival. Interactions between tumor-specific TFH and GC B cells are crucial for tumor control and effector CD8 T cell function.
Article
Biotechnology & Applied Microbiology
Yongsheng Jia, Krithika N. Kodumudi, Ganesan Ramamoorthi, Amrita Basu, Colin Snyder, Doris Wiener, Shari Pilon-Thomas, Payal Grover, Hongtao Zhang, Mark Greene, Qianxing Mo, Zhongsheng Tong, Yong-Zi Chen, Ricardo L. B. Costa, Hyo Han, Catherine Lee, Hatem Soliman, Jose R. Conejo-Garcia, Gary Koski, Brian J. Czerniecki
Summary: The study reveals the impact of Th1 immune response on HER2 breast cancer, showing that IFN-gamma can regulate HER2 through the PDP pathway. Treatment with IFN-gamma or Th1-polarizing anti-HER2 vaccine can lead to decreased surface HER2 expression and induction of tumor senescence in HER2-resistant mammary carcinoma, demonstrating therapeutic potential through anti-tumor immunity.
Article
Oncology
Ganesan Ramamoorthi, Krithika Kodumudi, Corey Gallen, Nadia Nocera Zachariah, Amrita Basu, Gabriella Albert, Amber Beyer, Colin Snyder, Doris Wiener, Ricardo L. B. Costa, Brian J. Czerniecki
Summary: Metastatic spread in breast cancer patients is the main cause of cancer-related deaths. Understanding the biological mechanisms of breast cancer cell dissemination, dormancy, and reactivation is important. This review discusses the molecular pathways involved in breast cancer cell dissemination, the role of chemokine-chemokine receptor networks in DCCs migration, DCCs phenotypic heterogeneity, and unique gene signatures in tumor dormancy.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Immunology
Susmita Srivastava, Snigdha Samarpita, Ramamoorthi Ganesan, Mahaboobkhan Rasool
Summary: This study demonstrates that CYT387 inhibits proliferation, migration, and pathogenic disease potential of FLS isolated from adjuvant-induced arthritic (AA) rats by targeting the IL-6/JAK1/STAT3 signaling cascade.
IMMUNOLOGICAL INVESTIGATIONS
(2022)
Article
Oncology
Amrita Basu, Gabriella K. Albert, Sabrina Awshah, Jashodeep Datta, Krithika N. Kodumudi, Corey Gallen, Amber Beyer, Keiran S. M. Smalley, Paulo C. Rodriguez, Derek R. Duckett, Peter A. Forsyth, Aixa Soyano, Gary K. Koski, Ricardo Lima Barros Costa, Heather Han, Hatem Soliman, Marie Catherine Lee, Pawel Kalinski, Brian J. Czerniecki
Summary: This study identifies immunogenic MHC class II-binding HER3 peptides that elicit HER3-specific CD4(+) Th1 responses, suggesting their potential application in immunotherapies for HER3-overexpressing tumors.
CANCER IMMUNOLOGY RESEARCH
(2022)
Review
Immunology
Nadia Nocera Zachariah, Amrita Basu, Namrata Gautam, Ganesan Ramamoorthi, Krithika N. Kodumudi, Nagi B. Kumar, Loretta Loftus, Brian J. Czerniecki
Summary: Breast cancer prevention is crucial for reducing the global burden of invasive breast cancer, with surgery and chemoprevention as main risk-reducing modalities. Immune-based cancer prevention shows advantages over drug-based chemoprevention, highlighted by successful dendritic cell vaccines targeting HER2-expressing BC. Strong immune response is necessary for target lesion elimination to prevent immunoediting and potential interception of IBC development through interrupting premalignant lesions.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Namrata Gautam, Kelly M. Elleson, Ganesan Ramamoorthi, Brian J. Czerniecki
Summary: This review discusses the standard treatments for metastatic breast cancer, focusing on the rationale for targeted therapy and the significance of immune response in immunotherapeutic studies. It provides an overview of various types of adoptive cell therapy in breast cancer and summarizes the clinical data regarding their use. Future adoptive cell therapy approaches for curing breast cancer are also proposed.
Article
Oncology
Ganesan Ramamoorthi, Krithika Kodumudi, Colin Snyder, Payal Grover, Hongtao Zhang, Mark Greene, Amrita Basu, Corey Gallen, Doris Wiener, Ricardo L. B. Costa, Hyo S. Han, Gary Koski, Brian J. Czerniecki
Summary: HER2-DC1 i.t. combined with anti-HER2 antibodies mediates tumor regression through combined activation of T and B cell compartments and provides evidence that HER2-DC1 i.t. in combination with anti-HER2 antibodies can be tested as an effective alternative therapeutic strategy to current chemotherapy and anti-HER2 antibodies in HER2(pos) BC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)